Mantle cell lymphoma: At last, some hope for successful innovative treatment strategies

被引：13

作者：

Fisher, RI ^{[1
]}

机构：

[1] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 04期

关键词：

D O I：

10.1200/JCO.2005.10.980

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：657 / 658

页数：2

共 12 条

[1]

Assouline S, 2003, BLOOD, V102, p902A

[2] MANTLE CELL LYMPHOMA - A PROPOSAL FOR UNIFICATION OF MORPHOLOGICAL, IMMUNOLOGICAL, AND MOLECULAR-DATA [J].

BANKS, PM ;

CHAN, J ;

CLEARY, ML ;

DELSOL, G ;

DEWOLFPEETERS, C ;

GATTER, K ;

GROGAN, TM ;

HARRIS, NL ;

ISAACSON, PG ;

JAFFE, ES ;

MASON, D ;

PILERI, S ;

RALFKIAER, E ;

STEIN, H ;

WARNKE, RA .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (07) :637-640

[3]

Chan WC, 1997, BLOOD, V89, P3909

[4]

Dunleavy KM, 2003, BLOOD, V102, p636A

[5] A CLINICAL ANALYSIS OF 2 INDOLENT LYMPHOMA ENTITIES - MANTLE CELL LYMPHOMA AND MARGINAL ZONE LYMPHOMA (INCLUDING THE MUCOSA-ASSOCIATED LYMPHOID-TISSUE AND MONOCYTOID B-CELL SUBCATEGORIES) - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].

FISHER, RI ;

DAHLBERG, S ;

NATHWANI, BN ;

BANKS, PM ;

MILLER, TP ;

GROGAN, TM .

BLOOD, 1995, 85 (04) :1075-1082

[6] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [J].

Foran, JM ;

Rohatiner, AZS ;

Cunningham, D ;

Popescu, RA ;

Solal-Celigny, P ;

Ghielmini, M ;

Coiffier, B ;

Johnson, PWM ;

Gisselbrecht, C ;

Reyes, F ;

Radford, JA ;

Bessell, EM ;

Souleau, B ;

Benzohra, A ;

Lister, TA .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :317-324

[7] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma [J].

Goy, A ;

Younes, A ;

McLaughlin, P ;

Pro, B ;

Romaguera, JE ;

Hagemeister, F ;

Fayad, L ;

Dang, NH ;

Samaniego, F ;

Wang, M ;

Broglio, K ;

Samuels, B ;

Gilles, F ;

Sarris, AH ;

Hart, S ;

Trehu, E ;

Schenkein, D ;

Cabanillas, F ;

Rodriguez, AM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :667-675

[8]

HIDDEMANN W, 2004, P AN M AM SOC CLIN, V23, P556

[9] Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival [J].

Howard, OM ;

Gribben, JG ;

Neuberg, DS ;

Grossbard, M ;

Poor, C ;

Janicek, MJ ;

Shipp, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1288-1294

[10] Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma [J].

Khouri, IF ;

Romaguera, J ;

Kantarjian, H ;

Palmer, JL ;

Pugh, WC ;

Korbling, M ;

Hagemeister, F ;

Samuels, B ;

Rodriguez, A ;

Giralt, S ;

Younes, A ;

Przepiorka, D ;

Claxton, D ;

Cabanillas, F ;

Champlin, R .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3803-3809

← 1 2 →